SKLB-261

N/A

Report date: 2026/05/08 20:02:52
NME

Base Information

Drug NameSKLB-261
Drug Alias NameSKLB-261
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsVascular endothelial growth factor receptor 2 inhibitors
TargetsVascular endothelial growth factor receptor 2Epidermal growth factor receptor erbB1
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSichuan University
China Registration ClassN/A

Develop Information

Active CompaniesSichuan University
Inactive CompaniesN/A
Active IndicationsPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A